India
· Delayed Price · Currency is INR NATCO Pharma Statistics
Total Valuation
NATCO Pharma has a market cap or net worth of INR 142.92 billion. The enterprise value is 120.44 billion.
| Market Cap | 142.92B |
| Enterprise Value | 120.44B |
Important Dates
The last earnings date was Tuesday, February 11, 2025.
| Earnings Date | Feb 11, 2025 |
| Ex-Dividend Date | Feb 18, 2025 |
Share Statistics
NATCO Pharma has 179.11 million shares outstanding. The number of shares has decreased by -0.71% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 179.11M |
| Shares Change (YoY) | -0.71% |
| Shares Change (QoQ) | -0.07% |
| Owned by Insiders (%) | 29.91% |
| Owned by Institutions (%) | 17.22% |
| Float | 83.48M |
Valuation Ratios
The trailing PE ratio is 7.66 and the forward PE ratio is 7.60. NATCO Pharma's PEG ratio is 0.27.
| PE Ratio | 7.66 |
| Forward PE | 7.60 |
| PS Ratio | 3.34 |
| PB Ratio | 2.00 |
| P/TBV Ratio | 2.07 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | 0.27 |
Enterprise Valuation
| EV / Earnings | 6.46 |
| EV / Sales | 2.81 |
| EV / EBITDA | 5.58 |
| EV / EBIT | 6.15 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.10 |
| Debt / FCF | n/a |
| Interest Coverage | 93.28 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 18.97% |
| Return on Capital Employed (ROCE) | n/a |
| Revenue Per Employee | 10.66M |
| Profits Per Employee | 4.64M |
| Employee Count | 4,016 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -23.36% in the last 52 weeks. The beta is 0.55, so NATCO Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.55 |
| 52-Week Price Change | -23.36% |
| 50-Day Moving Average | 1,233.46 |
| 200-Day Moving Average | 1,307.89 |
| Relative Strength Index (RSI) | 21.19 |
| Average Volume (20 Days) | 1,514,859 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NATCO Pharma had revenue of INR 42.80 billion and earned 18.65 billion in profits. Earnings per share was 104.13.
| Revenue | 42.80B |
| Gross Profit | 36.65B |
| Operating Income | 19.59B |
| Pretax Income | 22.63B |
| Net Income | 18.65B |
| EBITDA | 21.56B |
| EBIT | 19.59B |
| Earnings Per Share (EPS) | 104.13 |
Balance Sheet
The company has 24.63 billion in cash and 2.08 billion in debt, giving a net cash position of 22.55 billion or 125.90 per share.
| Cash & Cash Equivalents | 24.63B |
| Total Debt | 2.08B |
| Net Cash | 22.55B |
| Net Cash Per Share | 125.90 |
| Equity (Book Value) | 71.57B |
| Book Value Per Share | 399.14 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 85.62%, with operating and profit margins of 45.77% and 43.58%.
| Gross Margin | 85.62% |
| Operating Margin | 45.77% |
| Pretax Margin | 52.88% |
| Profit Margin | 43.58% |
| EBITDA Margin | 50.37% |
| EBIT Margin | 45.77% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 6.00, which amounts to a dividend yield of 0.75%.
| Dividend Per Share | 6.00 |
| Dividend Yield | 0.75% |
| Dividend Growth (YoY) | -36.84% |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.71% |
| Shareholder Yield | 1.46% |
| Earnings Yield | 13.05% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on November 26, 2015. It was a forward split with a ratio of 5.
| Last Split Date | Nov 26, 2015 |
| Split Type | Forward |
| Split Ratio | 5 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |